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ABSTRACT
Protective antigens are specifically targeted by the
acquired immune response of the host and are able
to induce protection in the host against infectious
and non-infectious diseases. Protective antigens
play important roles in vaccine development, as bio-
logical markers for disease diagnosis, and for
analysis of fundamental host immunity against
diseases. Protegen is a web-based central
database and analysis system that curates, stores
and analyzes protective antigens. Basic antigen
information and experimental evidence are curated
from peer-reviewed articles. More detailed gene/
protein information (e.g. DNA and protein se-
quences, and COG classification) are automatically
extracted from existing databases using internally
developed scripts. Bioinformatics programs are
also applied to compute different antigen features,
such as protein weight and pI, and subcellular
localizations of bacterial proteins. Presently, 590
protective antigens have been curated against
over 100 infectious diseases caused by pathogens
and non-infectious diseases (including cancers and
allergies). A user-friendly web query and visualiza-
tion interface is developed for interactive protective
antigen search. A customized BLAST sequence
similarity search is also developed for analysis of
new sequences provided by the users. To support
data exchange, the information of protective
antigens is stored in the Vaccine Ontology (VO) in
OWL format and can also be exported to FASTA
and Excel files. Protegen is publically available at
http://www.violinet.org/protegen.
INTRODUCTION
Human and animal health is threatened by various
diseases every day. Acquired as a result of pathogenic
microbial agents, infectious diseases are still a major
source of mortality throughout the world, contributing
to 26% of global mortality in 2001 (1). Of these
mortalities, 90% are caused by illnesses such as acute
respiratory infections, diarrheal diseases, malaria, AIDS,
tuberculosis and measles. Cancer, allergy and many other
diseases also cause signiﬁcant mortality and morbidity in
human and animal victims.
Vaccines stimulate the immune system and confer pro-
tection against pathogenic microorganisms, offering a safe
effective method to prevent disease. Vaccines are among
the most useful and cost-effective tools for reducing the
morbidity and mortality caused by infectious diseases.
Vaccination programs have succeeded in eliminating
smallpox from the world population as well as in drastic-
ally reducing the incidences of other diseases such as polio.
Measles, one of the six major illnesses responsible for mor-
tality mentioned above, can now be prevented by vaccin-
ation. Vaccines are also being developed for ﬁghting
against other diseases such as cancer and allergy.
At the forefront of this vaccine development are pro-
tective antigens. Protective antigens are those antigens
that are speciﬁcally targeted by the acquired immune
response of the host, and when introduced into the host
body, are able to stimulate the production of antibodies
and/or cell-mediated immunity against certain pathogens
or the causes of other diseases. Protective antigens can be
used in many research areas. First, identiﬁcation of pro-
tective antigens is a major component of research for new
and improved vaccines against infectious diseases (2).
Using these protective antigens, researchers are able to
develop vaccines, such as DNA and subunit vaccines,
which use targeted antigen DNA or proteins to elicit a
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great potential in the ﬁght against diseases such as malaria
for which there is no current vaccine. Protective antigens
are also useful in the control of allergies through the use of
allergen immunotherapy. This process uses repeated
exposure to allergenic antigens in order to create immuno-
logic tolerance in an individual to the allergen (3). Many
cancer vaccines are currently in clinical trials (4).
In addition, protective antigens can often be used as bio-
logical markers for diagnosis of diseases such as AIDS
based on the presence or absence of a protective
antigen(s) (5). Furthermore, the identiﬁcation of protect-
ive antigens and the study of their roles in the induction of
host immunity against various diseases are crucial to the
elucidation of fundamental host immune mechanisms.
While intensive research has been conducted and
resulted in identiﬁcation of many protective antigens,
these is no reported central resource that allows storage,
annotation, comparison, and analysis of protective
antigens across different species. To address this chal-
lenge, we have developed Protegen (http://www.violinet
.org/protegen), a web-based protective antigen database
and analysis system. Protegen stores manually curated
protective antigens and associated information. It also
allows bioinformatics analysis and comparison of
various protective antigens.
SYSTEM AND DATABASE DESIGN
Protegen is implemented using a three-tier architecture
built on two Dell Poweredge 2580 servers which run the
Redhat Linux operating system (Redhat Enterprise Linux
ES 4). Users can submit database or analysis queries
through the web. These queries are then processed using
PHP/SQL (middle-tier, application server based on
Apache) against a MySQL (version 5.0) relational
database (back-end, database server). The result of each
query is then presented to the user in the web browser.
Two servers are scheduled to regularly backup each
others’ data. Protegen is an integrated program of the
VIOLIN vaccine database and analysis (6).
Supplementary Figure S1 demonstrates the Protegen
database schema. For each speciﬁc protective antigen,
the Protegen database contains the following information:
(i) Detailed reference citation information, for example,
authors, journal, title, year, volume, issue, and pages.
These references are typically obtained from PubMed
(http://www.ncbi.nlm.nih.gov/pubmed), and used to
obtain experimental evidence that conﬁrms a protein’s
molecular role as a protective antigen. (ii) General infor-
mation of protective antigens, for example, gene symbol,
protein name, protein function, NCBI Gene ID, NCBI
Nucleotide ID, NCBI Protein GI, locus tag, NCBI
taxonomy ID, Cluster of Orthologous Groups (COG)
category (7), chromosome number, segment number,
plasmid number, gene starting and ending position, gene
strand orientation and DNA and protein sequences. These
data can be automatically extracted and updated from
existing databases (e.g. NCBI RefSeq database) using an
internally developed program. (iii) Protein 3D structure
stored in the Protein Data Bank (http://www.pdb.org).
This information is manually curated. (iv) Calculated
results (e.g. protein weight and pI, and subcellular local-
izations of bacterial protective antigens) based on DNA or
protein sequences with reliable bioinformatics software
programs. (v) Customized BLAST libraries containing
DNA or protein sequences of all protective antigens in
Protegen. The customized Protegen BLAST libraries can
be used for BLAST sequence similarity searches.
SEMI-AUTOMATIC ANNOTATION OF
PROTECTIVE ANTIGENS
A semi-automatic annotation system is developed in
Protegen for protective antigen curation and analysis
(Figure 1). This annotation system includes manual
curation from selected peer-reviewed publications and bio-
informatics extraction and analysis of DNA and protein
sequences of protective antigens. Manual curation of
peer-reviewed journal articles emphasizes the retrieval
of antigen information [e.g. protein/gene names and
database identiﬁers (IDs)] and experimental evidence.
Strong experimental evidence, particularly results from a
protection assay against speciﬁc challenge or an immune
response assay that correlates with protection, is required
to justify a protein being a protective antigen. It is a major
task to identify and record such direct experimental
evidence for individual protective antigens stored in
Protegen. In many cases, curated journal articles contain
database IDs for individual proteins or genes, such as
NCBI Gene ID, NCBI GenBank nucleotide ID or
NCBI protein accession number. If no database ID is
provided in curated publication, an ID can be found by
search a NCBI database using the species/strain and
protein/gene information from the article. Using a NCBI
Gene/Nucleotide/Protein identiﬁer, three scripts were de-
veloped to automatically extract related protein/gene in-
formation from corresponding database(s), such as DNA
and protein sequence, gene description, and protein notes.
These scripts can speed up the curation process and ensure
data accuracy. The extracted results are automatically dis-
played on an online form and can be subject to further
reviews and updates.
The DNA and protein sequences can further be used for
more bioinformatics analyses (Figure 1). For example,
protein weight and protein pI values are calculated using
functions in BioPHP (http://genephp.sourceforge.net/).
Subcellular localizations are predicted using PSORTb
(8). The transmembrane helix domain analysis is per-
formed using optimized HMMTOP (9). Adhesin probabil-
ity is predicted using optimized SPAAN (10). The last
three programs are also used in the Vaxign reverse
vaccinology program (http://www.violinet.org/vaxign) de-
veloped by our group (11). Reverse vaccinology is an
emerging vaccine design strategy that initiates the
process by bioinformatically screening vaccine candidates
from pathogenic genome databases based on different
criteria (12). Vaxign is the ﬁrst web-based system for
genome-wide reverse vaccinology analysis. Subcellular
localization, transmembrane domain and adhesin
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vaccine candidate prediction in reverse vaccinology.
These programs are used in Protegen to support further
comparison and analyses of known protective antigens.
The semi-automatic Protegen annotation system is de-
veloped by modifying an in-house web-based literature
mining and curation system called Limix (13,14). The
interactive Limix data submission and review system:
(i) allows a curator to search literature, copy and edit
text, and submit data to database and (ii) provides a
data reviewer tools to review, edit, and approve the
curated data on one comprehensive web interface. Limix
also features automated reference tracking and manage-
ment using a version control mechanism similar to that
used in Wikipedia (http://www.wikipedia.org/). The
system stores all the history changes made to every
antigen. A reviewer can compare any two of the history
versions to trace the detailed changes made to an antigen.
Supplementary Figure S2 provides a more detailed view of
the Limix curation process and reviewing features. Upon
approval after the critical review, the data will be posted
publicly.
Currently, Protegen has included 590 protective
antigens. Among these protective antigens, 539 come
from 44 bacteria, 40 viruses, 19 parasites and one fungal
species, which cause various infectious diseases (Table 1
and Supplementary Table S1). Examples of pathogens
include Bacillus anthracis (anthrax), Brucella spp. (brucel-
losis), Yersinia pestis (Plague), Human immunodeﬁciency
virus (HIV, the causative agent of AIDS), Ebola virus
(hemorrhagic fever) and Plasmodium spp. (malaria).
Protegen also stores 59 protective antigens for cancer,
allergies and a plant (ricin) toxin. Research into protective
antigens against cancer and common allergens is an im-
portant ﬁeld of research as both cancer and allergies cause
mortality and morbidity just as infectious diseases do.
Cancer vaccine development strategies focus on antigens
to immunize cancer patients with to stimulate their own
immune system, and thus are more treatment oriented
than prevention based. The same approach is true for
allergies, with the goal being to prevent an allergic
response, in patients with known allergies to speciﬁc
allergens.
Protegen is targeted to be updated quarterly with add-
itional protective antigens and their bioinformatics
analyses. All Protegen updates are posted in the
Protegen website.
PROTECTIVE ANTIGEN DATA QUERY AND
DISPLAY
The manually curated and pre-computed Protegen data
can be efﬁciently queried and visualized as demonstrated
in Figure 2. The protective antigens can be queried by
specifying one or multiple criteria: (i) gene or protein
name, (ii) pathogen species or strain, (iii) locus tag of a
protective antigen, (iv) other existing database identiﬁers,
such as NCBI Gene ID, NCBI nucleotide or protein GI,
(v) keywords search with Boolean mode support, (vi)
COG category, (vii) subcellular localization, (viii) four
limiting factors, including the maximum number of trans-
membrane helices, the minimum adhesin probability, and
protein sequence similarity to human proteins, and
protein sequence similarity to mouse proteins (Figure 2A).
All query hits are ﬁrst displayed on a web table contain-
ing basic antigen information (Figure 2B). Individual pro-
tective antigens can further be selected by a user to show
more detailed information (Figure 2C). Other dynamic
analysis of protective antigens, such as BLAST sequence
similarity analysis, can be implemented (Figure 2D).
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Figure 1. Semi-automatic annotation of protective antigens in Protegen overall design and architecture. Manual curation includes peer-reviewed
publications from PubMed. A PubMed ID (PMID) is extracted and used to retrieve detailed citation information (e.g. authors, journal, and date).
The evidence that proves the status of protective antigen for each protein is curated from published experimental studies. Vaccines associated with
the protective antigens are also curated. PDB IDs are manually retrieved when available to provide 3D structure information of individual protective
antigens. Internally developed script uses an input sequence ID from a NCBI database (e.g. NCBI Entrez Gene database) to automatically retrieve
different types of information. The extracted DNA and protein sequences are further used for bioinformatics analyses using different methods.
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To facilitate antigen comparison and dynamical sequence
analysis, two customized BLAST libraries have been
generated. One library contains the protein sequences of
all protective antigens in Protegen, and the other collects
all the DNA sequences of all protective antigens. The
Protegen users are able to perform BLAST sequence simi-
larity searches using different NCBI BLAST (http://blast
.ncbi.nlm.nih.gov/Blast.cgi), including blastp, blastn,
blastx, tblastn and tblastx, against the customized
Protegen libraries. The customized BLAST programs in
Protegen can be used in two different applications. The
ﬁrst is to allow a user to compare a known protective
antigen(s) in Protegen with other protective antigens. An
example of such a BLAST search is demonstrated in
Figure 2D. The second application is to allow a user to
input any protein or DNA sequence(s) into the Protegen
BLAST online form, and identify those protective
antigens that share similar protein or DNA sequences
with the input sequence(s).
Other dynamic analyses of protective antigens are also
available. For example, each protective antigen can be
linked to Vaxign for more reverse vaccinology analyses
(e.g. immune epitope prediction).
DATA TRANSFER AND DOWNLOAD
To facilitate data exchange and transfer, the information
of protective antigens in Protegen is now stored in
the Vaccine Ontology (VO; http://www.violinet.org/
vaccineontology) (15). VO is a community-based
ontology in the vaccine domain. It is developed based
on the OWL format, which can be processed by many
existing software programs and used for Semantic Web
applications. The storage of protective antigens in VO
allows development of new software programs to integrate
the protective antigen data with other biomedical data and
support further bioinformatics analyses. Users can also
export selected protective antigen information into a
Microsoft Excel document. The FASTA sequence
format has frequently been used for ﬂexible bioinformatics
analyses. Protegen provides free downloads of FASTA
ﬁles of merged or grouped DNA or protein sequences of
protective antigens.
DISCUSSION
A few challenges have been identiﬁed throughout the
curation process. One challenge is that a protective
antigen is often hard to identify for many less studied
pathogens (e.g. Bordetella avium) and less fatal diseases.
In many cases, after a protective antigen was identiﬁed,
the pathogen strains available from NCBI frequently did
not match up with the strains used in the experimental
challenge study. Unless the two strains had conserved
regions of DNA for the protective antigen, we could not
use these studies for inclusion in Protegen. Furthermore,
many challenge studies would design a successful potential
vaccine that expressed two or more distinct proteins. In
our curation, these challenge studies are not typically used
since it is difﬁcult to conclude whether each individual
protein induces protection in vivo. In case such challenge
studies were included in our curation, speciﬁc notes were
added to the section of experimental evidence (i.e.
Molecular Annotations of antigens).
Computational and informatics technologies have
been used to support immunology and vaccine develop-
ment for decades (16). Prediction and analysis of immune
epitopes have been emphasized from the beginning. As a
result, many high quality immune epitope databases
and programs, such as IEDB (17) and MHCPred (18),
have been developed. Many comprehensive reviews
on this topic can be found in the literature (16,19).
Recently there has been a trend to study other aspects
including immunogenic antigens and protective antigens.
AntigenDB is a newly reported database focused on col-
lection of immunogenic antigens (20). AntigenDB collects
antigen information from selected pathogen species.
Table 1. Curated protective antigens from select pathogens as of
14 August 2010
Pathogen (Disease name) Number of
protective
antigens
Bacteria (10 out of 44)
Brucella spp. (Brucellosis) 19
B. pertussis (Whooping cough) 10
C. abortus (Pelvic inﬂammatory disease) 10
E. coli (Hemorrhagic colitis) 17
F. tularensis (Tularemia) 10
H. inﬂuenzae (Pneumonia, bacterial meningitis) 14
M. tuberculosis (Tuberculosis) 24
N. meningitidis (Meningitis) 19
S. pneumoniae (Pneumonia) 12
Y. pestis (Plague) 24
Viruses (10 out of 40)
Dengue virus (Dengue fever) 4
Ebola virus (Hemorrhagic fever) 13
Herpes simplex virus type 1 and type 2 (Herpes) 9
Human Immunodeﬁciency Virus (AIDS) 5
Human papillomavirus (HPV) 4
Inﬂuenza virus (Inﬂuenza) 37
Japanese encephalitis virus (Japanese encephalitis) 6
Marburg virus (Hemorrhagic fever) 6
Pseudorabies virus (Aujeszky’s disease) 8
Rotavirus (Severe diarrhea) 8
Parasites (10 out of 19)
Babesia bovis (Babesiosis) 3
Eimeria tenella (hemorrhagic cecal coccidiosis) 5
Entamoeba histolytica (Amebiasis) 4
Leishmania amazonensis (Leishmaniasis) 5
Leishmania donovani (Visceral leishmaniasis) 11
Leishmania major (Cutaneous leishmaniasis) 10
Neospora caninum (Neosporosis) 8
Plasmodium spp. (Malaria) 26
Toxoplasma gondii (Toxoplasmosis) 3
Trypanosoma cruzi (Chagas Disease) 9
Others
Allergy 14
Cancer 36
Ricin Toxin 1
Coccidioides spp. (Coccidioidomycosis) 9
Total 403
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that Protegen only includes those antigens that induce
protection against virulent challenge in vivo or stimulate
a speciﬁc immune response(s) that correlate with protec-
tion. AntigenDB includes antigens that stimulate immune
responses but do not necessarily induce protection or
protective immune response. For example, AntigenDB
includes 73 antigens from Mycobacterium tuberculosis.
Based on our manual curation and analysis, only 14 out
of the 73 antigens were experimentally veriﬁed to induce
protection in vivo and can be classiﬁed as protective
antigens in Protegen. Not all immunogenic antigens can
be used for vaccine development. For example, M. tuber-
culosis LppX (21) and Hsp65 (22) are both highly
immunogenic but not protective against tuberculosis.
To the best of our knowledge, Protegen is the ﬁrst
web-based, publically available database and analysis
system that targets for the curation and analysis of
protective antigens.
In addition, Protegen has several other unique features
compared to AntigenDB. First, Protegen manually
curates and stores experimental evidence for each protect-
ive antigen. Second, Protegen covers a broad range of
diseases, including infectious diseases caused by more
than 100 pathogen species and many non-infectious
diseases (e.g. cancers and allergies). Third, Protegen
includes bioinformatics analysis of weight, pI, transmem-
brane domain, adhesin probability for each protective
antigen stored in Protegen. Protegen also provides links
to the new Vaxign vaccine design program.
VIOLIN is the ﬁrst web-based vaccine database and
analysis system that targets for vaccine research (6).
Currently VIOLIN has included 745 vaccines and
vaccine candidates for infectious diseases caused by over
100 pathogens and many non-infectious diseases. Several
new programs (e.g. Vaxign, VO and Protegen) have been
developed in VIOLIN. Protegen is not just one part of
further VIOLIN development. Protegen is a new and rela-
tively independent program, and the usage of protective
antigens collected in Protegen may go beyond vaccine
research and be used for diagnosis and immune mechan-
ism studies.
Figure 2. Example of protective antigen query and BLAST sequence similarity analysis. A COG category search of ‘Cell wall/membrane/envelope
biogenesis’ in conjunction with a subcellular localization search of ‘Outer Membrane’ (A) identiﬁed 11 genes from the Protegen database, including
Pla from Yersinia pestis strain CO92, and Pal from Haemophilus inﬂuenza strain 86-028NP (B). Clicking the Protegen antigen ID associated with Pla
provided curated data including the sequence strain, NCBI Gene GI, NCBI Protein GI, protein name, NCBI taxonomy ID, DNA and protein
sequences as well as other information (C). A BLAST sequence similarity analysis of the DNA sequence produced multiple hits with signiﬁcant
alignments (D).
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tions. For example, the protective antigens can be used as
positive controls for rational vaccine design. It has long
been suggested that those pathogens (e.g. E. coli) against
which a strong antibody (B cell) response is critical,
surface-exposed outer membrane proteins and secreted
proteins are ideal targets for vaccine development.
However, to develop vaccines against those pathogens
(e.g. Brucella spp.) where T cell response is critical,
subcellular localization may not be an issue since a
T cell response could be directed to any protein target.
Such a phenomenon can be veriﬁed by examining pre-
dicted subcellular localizations for all bacterial protective
antigens in Protegen (Supplementary Figure S2). The
Protegen protective antigens can also be used for
analysis of protective immune epitopes. Protein structural
analysis can signiﬁcantly aid the rational design of future
vaccines. One key towards a next generation rational
vaccine design is the ability to apply structure-oriented
bioinformatics to predict immune peptide epitopes ideal
for vaccine development (12). We hypothesize that many
protective antigens preserve some unique epitope informa-
tion which would support further vaccine development
and immune response studies. Such a hypothesis is cur-
rently under investigation. The atomic resolution of the
structures of protective antigens may lead to the rational
design of target epitopes as vaccine candidates.
More protective antigens will be added to Protegen.
More diseases will also be covered. Currently Protegen is
focused on curation of protective protein antigens. We are
also in the process of annotating other types of protective
antigens. For example, bacterial LPSs from many bacteria
(e.g. Brucella) have been found to be protective antigens.
Protegen is targeted to become a central and vital source
of protective antigens and will support researchers in the
areas of vaccinology, microbiology, and immunology with
curated data and bioinformatics tools. We believe that
Protegen is a timely repository and will have signiﬁcant
impact for vaccine research and development and other
applications.
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